Machine Readable Form/Legible copy of Financial Results
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 26 Jun 2026, 12:37 PM IST · BSE ID: f7de63a4-9c0a-4392-a461-f4c5483e93dc
View Original BSE Filing (PDF)
💡
In Simple Terms
Marksans Pharma refiled its annual financial results for March 2026 in a readable format, showing significant profit growth.
🤖 AI Summary
- Marksans Pharma submitted legible audited financial results for the quarter and year ended March 31, 2026.
- The submission rectifies a previous filing on May 26, 2026, which was not machine-readable.
- Total income for the year ended March 31, 2026, was 14,450.09 million, compared to 12,401.61 million last year.
- Profit After Tax for FY26 stood at 3,006.98 million, up from 1,882.72 million in FY25.
- Basic Earnings Per Share for the year ended March 31, 2026, was 6.64.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Year ended 31 Mar 2026)
13,414.76 million
14.23%
Total Income (Year ended 31 Mar 2026)
14,450.09 million
16.52%
Profit Before Tax (Year ended 31 Mar 2026)
3,915.43 million
61.79%
Profit After Tax (Year ended 31 Mar 2026)
3,006.98 million
59.71%
Basic Earnings per equity share (Year ended 31 Mar 2026)
6.64
60.00%
🏢 How This Affects the Company
The re-submission of financial results confirms the reported financial performance for FY26, including total income of 14,450.09 million and profit after tax of 3,006.98 million.
The company acknowledged an oversight in its previous filing, stating it will prevent such occurrences in the future, addressing a minor compliance risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this re-submission.
👤
Who Is Affected
All shareholders now have access to the complete and properly formatted audited financial results for the year ended March 31, 2026, which were previously submitted on May 26, 2026.
🔍
Management Signal
Management acknowledged and rectified an administrative oversight in the financial reporting process, indicating a commitment to regulatory compliance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor revenue and profit after tax figures.
Any further compliance-related disclosures from the company.
Updates on the proposed Rs. 0.90 final dividend per share.
LOW RISK
This filing corrects a procedural error with no change to financial data.
💡 Investor Takeaway
Marksans Pharma has re-submitted its Audited Standalone Financial Results for the year ended March 31, 2026, in a machine-readable format. The results confirm a Profit After Tax of 3,006.98 million for FY26, an increase from 1,882.72 million in FY25, and basic EPS of 6.64.
⚖️ Strengths & Concerns
✅ Positives
- Profit After Tax for the year ended March 31, 2026, increased to 3,006.98 million from 1,882.72 million in the prior year.
- Revenue from operations for FY26 grew to 13,414.76 million compared to 11,743.74 million in FY25.
⚠️ Concerns
- The need to resubmit financial results indicates an initial administrative oversight in regulatory compliance procedures.
📅 Company Track Record
Marksans Pharma previously reported audited financial results for the quarter and year ended March 31, 2026, on May 26, 2026, which included a proposed final dividend of Rs. 0.90 per share. This filing is a re-submission of the same data in a compliant format.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
Why did Marksans Pharma re-submit its financial results?
Marksans Pharma re-submitted its financial results because the initial submission on May 26, 2026, for the quarter and year ended March 31, 2026, was not in a machine-readable or legible format as requested by NSE.
What was Marksans Pharma's Profit After Tax for the year ended March 31, 2026?
Marksans Pharma's Profit After Tax for the year ended March 31, 2026, was 3,006.98 million, an increase from 1,882.72 million in the previous year.
What was Marksans Pharma's total income for the year ended March 31, 2026?
For the year ended March 31, 2026, Marksans Pharma reported a total income of 14,450.09 million, compared to 12,401.61 million for the year ended March 31, 2025.
What were the basic earnings per share for Marksans Pharma for FY26?
The basic earnings per equity share for Marksans Pharma for the year ended March 31, 2026, stood at 6.64, compared to 4.15 for the prior year.
Questions based on this BSE filing only. For information purposes.